GENVEC EXPANDS MALARIA VACCINE PROGRAM UNDER NMRC CONTRACT

GenVec has signed a $1.6 million contract with the Defense Department to manufacture an adenovector based malaria vaccine candidate for the U.S. Naval Medical Research Center (NMRC) using GenVec's proprietary adenovector technology and 293-ORF6 cell-line based manufacturing process.

The vaccine is based on two antigens and is designed to attack multiple stages in the life cycle of the P. falciparum malaria parasite. The NMRC will use some of the materials manufactured under this contract to complete preclinical testing in preparation for a planned clinical trial, which will be executed by the NMRC.